모바일 메뉴 Open
언어
RECRUITING

CHA Biotech

전체메뉴
모바일 메뉴 Close
RECRUITING
About
CEO
Message
Vision
& Mission
History
Corporate
Identity
Subsidiaries
Directions
Business
Overview
i-Cord
Cord Blood Bank
Bio
Insurance
CHAUM
IT
CDMO
Consulting
Genomics
R&D
Pipelines
Investors
Business Performance
IR
Presentations
ESG
ESG
Management
Environmental
Social
Governance
전체메뉴 닫기
About
CEO
Message
Vision
& Mission
History

2024

2023~2015

2014~2011

2010~2000

Corporate
Identity
Subsidiaries
Directions
Business
Overview
i-Cord Cord Blood Bank
Bio
Insurance
CHAUM
IT
CDMO

Overview of Matica BioLabs

CDMO Inquiry

Consulting
Genomics
R&D
Pipelines
Investors
Business Performance
IR
Presentations
ESG
ESG
Management
Environmental
Social
Governance

Articles of Incorporation

Board of Directors

Shareholders

Vision
& Mission

History

Corporate
Identity
2014
  • hESC-RPE (embryonic) therapy for Stargardt disease designated as an orphan drug by Korea’s Ministry of Food and Drug Safety
  • IND approval for CordSTEM®-ST Phase 1/2a clinical trial for acute stroke therapy
  • Establishment of Total Cell Clinic (TCC) in Japan for immune cell therapy
  • Strategic alliance between BioInsurance and TCC
2013
  • Establishment of CHA Healthcare (physical division of hospital operation business)
  • Establishment of CHA Meditech (physical division of medical device development business)
  • First domestic IND approval for hESC-RPE (embryonic) therapy for myopic macular degeneration
  • IND approval for Phase 2 clinical trial of PLX-PAD for intermittent claudication in Korea
2012
  • First domestic IND approval for hESC-RPE (embryonic) therapy for age-related macular degeneration
  • Recognition as a transparent management company by the Korean Accounting Association and the Korean Institute of Certified Public Accountants
  • Acquisition of CMG Pharmaceuticals (formerly Skynewpharm, KOSDAQ: 058820)
2011
  • Acquisition of CHA Vaccine Research Institute (formerly DooBiel)
  • First domestic IND approval for hESC-RPE (embryonic) therapy for Stargardt disease
  • Approval to open iCord Cord Blood Bank by Korea’s Ministry of Health and Welfare.
CHA Network
  • Company Name CHA Biotech Co., Ltd.
  • CEO Sang Hoon Oh
  • [Main Office] CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13488

  • TEL: +82-31-881-7400
  • FAX: +82-31-881-7524
  • [Headquarter] PIE’N POLUS Building, 442 Dosan-daero, Gangnam-gu, Seoul

COPYRIGHT ⓒ 2024 by CHA Biotech, All rights reserved.

Affiliates

Global Healthcare

Related

Business